Overcoming a Critical Shortage
Sourcing scarce potassium iodide following a nuclear disaster
Shortly after the Fukushima Daichi nuclear plant disaster in March 2011, a pharmaceutical client made an urgent request for potassium iodide to protect employees in Japan from radiation exposure. Fears of radiation poisoning in the wake of the disaster had led to stockpiling in the United States and elsewhere, virtually eliminating available supplies.
Members of the Caligor team who had gone through the 1986 Chernobyl disaster were aware of countries that held surplus supply. They contacted manufacturers in Austria that were able to support the necessary quantity.
Within just three days after the initial request, Caligor shipped potassium iodide to the customer free of charge.
Keeping a Clinical Trial on Track
Market insight leads to an effective comparator alternative
In 2012, the closure of a major U.S. lab caused a long-term shortage of an important generic oncology drug. One of our clients, a preeminent biotech company, had an ongoing trial that required immediate supply of this product.
Leveraging Caligor’s extensive market knowledge and regulatory relationships, we advised the client that the FDA was permitting temporary imports of a substitute drug manufactured in the European Union. We then identified potential supply sources in Poland, Romania, Germany, and the UK.
The product was imported into the U.S. a few weeks later, meeting our client’s urgent supply needs and avoiding a delay of their clinical trial.